Telomir Pharma announces resignation of director Michael Jerman; replaces audit committee roles
Telomir Pharmaceuticals, Inc.
On November 18, 2024, Michael Jerman resigned from the Board and as Chair of the Audit Committee, effective immediately, to pursue other activities, not due to a disagreement.
On November 20, 2024, the Board appointed Dr. Matthew Del Giudice to the Audit Committee to fill the vacancy.
The Board also appointed Matthew Pratt Whalen as Chairman of the Audit Committee.
No exhibits other than the Fifth Refinancing Amendment (not attached here) were filed.
On November 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the “ Board ”) and as Chair of the Audit Committee
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Michael Jerman resigned as Member of the Board of Directors and Chair of the Audit Committee at Telomir Pharmaceuticals, Inc..
Action
resigned
Role
Member of the Board of Directors and Chair of the Audit Committee
Exact text from the filing
On November 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the “ Board ”) and as Chair of the Audit Committee
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.